Literature DB >> 21606605

Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data.

Masataka Oitate1, Noriko Masubuchi, Takashi Ito, Yoshiyuki Yabe, Tsuyoshi Karibe, Takanori Aoki, Nobuyuki Murayama, Atsushi Kurihara, Noriko Okudaira, Takashi Izumi.   

Abstract

Interspecies allometric scaling is a useful tool for calculating human pharmacokinetic (PK) parameters from data in animals. In this study, in order to determine the scaling exponent in a simple allometric equation that can predict human clearance (CL) and distribution volume at steady state (Vss) of monoclonal antibodies (mAbs) from monkey data alone, PK data of 24 mAbs were collected and analyzed according to the types of targeted antigens (soluble or membrane-bound antigens). Based on the observed PK data in humans (at clinical doses) and monkeys (at >1 mg/kg), where the PK is expected to be linear, the mean scaling exponents in the allometric equation for CL and Vss, respectively, against body weight were calculated to be 0.79 and 1.12 [95% confidence intervals (CIs): 0.69-0.89 and 0.96-1.28] for soluble antigens, and 0.96 and 1.00 (95% CIs: 0.83-1.09 and 0.87-1.13) for membrane-bound antigens. Using these exponents and monkey PK data (at >1 mg/kg) alone, both human CL and Vss of mAbs can be predicted with reasonable accuracy, i.e., within 2-fold of the observed values. Compared with traditional allometric scaling using PK data from three or more preclinical species, this approach is simple, quick, resource-saving, and useful in drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606605     DOI: 10.2133/dmpk.dmpk-11-rg-011

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  27 in total

1.  Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.

Authors:  Miho Nagayasu; Kazuhisa Ozeki
Journal:  Pharm Res       Date:  2021-03-29       Impact factor: 4.200

2.  Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Authors:  Aman P Singh; Wojciech Krzyzanski; Steven W Martin; Gregory Weber; Alison Betts; Alaa Ahmad; Anson Abraham; Anup Zutshi; John Lin; Pratap Singh
Journal:  AAPS J       Date:  2014-12-03       Impact factor: 4.009

Review 3.  The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.

Authors:  Janice A Lansita; Barbara Mounho-Zamora
Journal:  Curr Pain Headache Rep       Date:  2015

Review 4.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

5.  Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.

Authors:  Lindsay B Avery; Jason Wade; Mengmeng Wang; Amy Tam; Amy King; Nicole Piche-Nicholas; Mania S Kavosi; Steve Penn; David Cirelli; Jeffrey C Kurz; Minlei Zhang; Orla Cunningham; Rhys Jones; Brian J Fennell; Barry McDonnell; Paul Sakorafas; James Apgar; William J Finlay; Laura Lin; Laird Bloom; Denise M O'Hara
Journal:  MAbs       Date:  2018-01-29       Impact factor: 5.857

6.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Authors:  Lindsay B Avery; Mengmeng Wang; Mania S Kavosi; Alison Joyce; Jeffrey C Kurz; Yao-Yun Fan; Martin E Dowty; Minlei Zhang; Yiqun Zhang; Aili Cheng; Fei Hua; Hannah M Jones; Hendrik Neubert; Robert J Polzer; Denise M O'Hara
Journal:  MAbs       Date:  2016-05-27       Impact factor: 5.857

7.  Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.

Authors:  Yanan Zheng; Devin B Tesar; Lisa Benincosa; Herbert Birnböck; C Andrew Boswell; Daniela Bumbaca; Kyra J Cowan; Dimitry M Danilenko; Ann L Daugherty; Paul J Fielder; Hans Peter Grimm; Amita Joshi; Nicole Justies; Gerry Kolaitis; Nicholas Lewin-Koh; Jing Li; Sami McVay; Jennifer O'Mahony; Michael Otteneder; Michael Pantze; Wendy S Putnam; Zhihua J Qiu; Jane Ruppel; Thomas Singer; Oliver Stauch; Frank-Peter Theil; Jennifer Visich; Jihong Yang; Yong Ying; Leslie A Khawli; Wolfgang F Richter
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

8.  A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  Eur J Pharm Sci       Date:  2019-08-05       Impact factor: 4.384

9.  Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.

Authors:  Alain P Vicari; Alain M Schoepfer; Bertrand Meresse; Laurence Goffin; Olivier Léger; Soheila Josserand; Nicolas Guégan; Shida Yousefi; Alex Straumann; Nadine Cerf-Bensussan; Hans-Uwe Simon; Yolande Chvatchko
Journal:  MAbs       Date:  2017-06-05       Impact factor: 5.857

10.  Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.

Authors:  Yulia Vugmeyster; Cynthia Rohde; Mylene Perreault; Ruth E Gimeno; Pratap Singh
Journal:  MAbs       Date:  2013-03-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.